{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-025128","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.803705+00:00","generated_at":"2026-05-21T17:16:19.765732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell Immunopharma reports Q1 net loss $52.2M; LYL314 RMAT designation and pivotal trial on track","bullets":["Net loss of $52.2M (GAAP) vs $60.7M YoY; non-GAAP net loss $46.3M vs $37.5M YoY.","Cash, equivalents and marketable securities $330.1M as of Mar 31, 2025; sufficient into 2027.","R&D expenses $43.4M, G&A $14.0M; workforce reduction and closure of West Hills facility impacted costs.","LYL314 granted RMAT designation by FDA for relapsed/refractory DLBCL in third-line setting.","Pivotal trial of LYL314 in third-line expected mid-2025; second-line pivotal trial by early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-025128","json":"https://secwatch.observer/filing/0001628280-25-025128.json","markdown":"https://secwatch.observer/filing/0001628280-25-025128.md","text":"https://secwatch.observer/filing/0001628280-25-025128.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/0001628280-25-025128-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000162828025025128/lyel-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:16:19.765732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}